The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
暂无分享,去创建一个
Andrea Lombardi Borgia | Antonella Isacchi | Roberta Bosotti | Laura Raddrizzani | Enrico Pesenti | Marco A Pierotti | Tiziano Bandiera | Alessio Somaschini | R. Bosotti | A. Isacchi | E. Felder | M. Pierotti | A. Borgia | T. Bandiera | D. Ballinari | F. Gasparri | A. Galvani | E. Pesenti | R. Alzani | S. Veronese | A. Sartore-Bianchi | M. Gambacorta | S. Siena | E. Ardini | L. Raddrizzani | Elena Ardini | Andrea Sartore-Bianchi | Salvatore Siena | Cristina De Ponti | Rosaria Cammarota | Nadia Amboldi | Andrea Milani | Paola Magnaghi | Dario Ballinari | Daniele Casero | Fabio Gasparri | Patrizia Banfi | Nilla Avanzi | Maria B Saccardo | Rachele Alzani | Eduard Felder | Daniele Donati | Marcello Gambacorta | Silvio Veronese | Arturo Galvani | N. Avanzi | C. De Ponti | D. Donati | Andrea Milani | A. Somaschini | P. Banfi | R. Cammarota | N. Amboldi | D. Casero | M. Saccardo | P. Magnaghi | Maria B. Saccardo | Marco A. Pierotti | Alessio Somaschini
[1] Amar Gajjar,et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.
[2] Jinkuk Kim,et al. NTRK1 Fusion in Glioblastoma Multiforme , 2014, PloS one.
[3] David M. Jones,et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. , 2014, The oncologist.
[4] Iwei Yeh,et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas , 2014, Nature Communications.
[5] Jeffrey A. Engelman,et al. Tyrosine kinase gene rearrangements in epithelial malignancies , 2013, Nature Reviews Cancer.
[6] L. Garraway,et al. Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer , 2013, Nature Medicine.
[7] J. Tabernero,et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.
[8] A. D’Incecco,et al. Targeted therapy for NSCLC with driver mutations , 2013, Expert opinion on biological therapy.
[9] M. Ladanyi,et al. ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[10] Seung-Yong Jeong,et al. Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing , 2013, PloS one.
[11] Angelo Nuzzo,et al. Cell line identity finding by fingerprinting, an optimized resource for short tandem repeat profile authentication. , 2013, Genetic testing and molecular biomarkers.
[12] Y. Indo,et al. Nerve growth factor and the physiology of pain: lessons from congenital insensitivity to pain with anhidrosis , 2012, Clinical genetics.
[13] Melanie A. Huntley,et al. Recurrent R-spondin fusions in colon cancer , 2012, Nature.
[14] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[15] Jeffrey W. Clark,et al. ROS1 rearrangements define a unique molecular class of lung cancers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[17] Doron Lipson,et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.
[18] A. Isacchi,et al. The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding , 2012, Molecular Diversity.
[19] A. Tsao,et al. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .
[20] F. Fiorentini,et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. , 2011, Bioorganic & Medicinal Chemistry Letters.
[21] G. Webersinke,et al. Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia , 2011, Diagnostic pathology.
[22] A. Isacchi,et al. 102 Identification and preclinical characterization of NMS-P626, a potent, selective and orally bioavailable TrkA inhibitor with anti-tumor activity in a TrkA-dependent colorectal cancer , 2010 .
[23] B. Nordlinger,et al. Colorectal cancer – Authors' reply , 2010, The Lancet.
[24] M. A. Pierotti,et al. Rearrangements of NTRK1 gene in papillary thyroid carcinoma , 2010, Molecular and Cellular Endocrinology.
[25] A. Bardelli,et al. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Bardelli,et al. Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer , 2009, Journal of the National Cancer Institute.
[27] D. Cunningham,et al. Treatment in advanced colorectal cancer: what, when and how? , 2009, British Journal of Cancer.
[28] Giovanni Parmigiani,et al. Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers , 2003, Nature Reviews Cancer.
[29] P. Sorensen,et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. , 2002, Cancer cell.
[30] D. Gisselsson,et al. ETV6 Rearrangements in Patients with Infantile Fibrosarcomas and Congenital Mesoblastic Nephromas by Fluorescence In Situ Hybridization , 2001, Modern Pathology.
[31] David R Kaplan,et al. Neurotrophin signal transduction in the nervous system , 2000, Current Opinion in Neurobiology.
[32] P. Sorensen,et al. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells , 2000, Oncogene.
[33] M. Pierotti,et al. A novel NTRK1 mutation associated with congenital insensitivity to pain with anhidrosis. , 1999, American journal of human genetics.
[34] G. Evan,et al. Specific TrkA survival signals interfere with different apoptotic pathways , 1998, Oncogene.
[35] P. Sorensen,et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma , 1998, Nature Genetics.
[36] M. Pierotti,et al. Chromosome I rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid‐specific TRK oncogenes , 1997, Genes, chromosomes & cancer.
[37] R. Stephens,et al. Autophosphorylation of Activation Loop Tyrosines Regulates Signaling by the TRK Nerve Growth Factor Receptor* , 1997, The Journal of Biological Chemistry.
[38] D. Kaplan,et al. Signal transduction by the neutrophin receptors , 1997 .
[39] D. Kaplan,et al. Signal transduction by the neurotrophin receptors. , 1997, Current opinion in cell biology.
[40] M. Borrello,et al. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. , 1995, Genomics.
[41] G. Yancopoulos,et al. Neurotrophic factors and their receptors , 1994, Annals of neurology.
[42] W. Snider,et al. Functions of the neurotrophins during nervous system development: What the knockouts are teaching us , 1994, Cell.
[43] T. Pawson,et al. Trk receptors use redundant signal transduction pathways involving SHC and PLC-γ1 to mediate NGF responses , 1994, Neuron.
[44] M. Pierotti,et al. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. , 1992, Oncogene.
[45] J. Bishop,et al. Nerve growth factor rapidly stimulates tyrosine phosphorylation of phospholipase C-gamma 1 by a kinase activity associated with the product of the trk protooncogene. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[46] A. Lupas,et al. Predicting coiled coils from protein sequences , 1991, Science.
[47] D. Kaplan,et al. The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. , 1991, Science.
[48] D. Kaplan,et al. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF , 1991, Nature.
[49] M. Barbacid,et al. Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain , 1990, Molecular and cellular biology.
[50] I. Fidler,et al. Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. , 1988, Cancer research.
[51] G. Daley,et al. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[52] Q. Sattentau,et al. HIV infection of primate lymphocytes and conservation of the CD4 receptor , 1987, Nature.
[53] R. Levi‐montalcini,et al. The nerve growth factor 35 years later. , 1987, Science.
[54] M. Barbacid,et al. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences , 1986, Nature.